Buprenorphine Maintenance and Acute Fracture Pain
Mr. R is a 58-year-old man with opioid use disorder maintained on buprenorphine-naloxone 16/4 mg daily for 2 years. He falls and sustains a displaced femoral neck fracture; ORIF is scheduled in 6 hours. In the ED he rates pain 9/10 and receives oxycodone 10 mg PO, with little change after 45 minutes. He is opioid-tolerant by history, takes no other medications, and has eGFR 72 mL/min/1.73 m². He is afebrile and hemodynamically stable. The orthopedic surgeon asks whether to continue buprenorphine before surgery and how to make him comfortable, while the anesthesia team worries about respiratory depression if full agonists are added.
1. Why is oxycodone 10 mg unlikely to provide adequate analgesia in this patient? Explain the receptor-level reasoning and its implications for choosing an analgesic strategy.
Read the worked answer
Buprenorphine is a high-affinity partial mu-opioid agonist with slow dissociation from the receptor. At 16 mg/day it occupies a large fraction of mu receptors, so a standard dose of oxycodone competes poorly and produces a blunted effect. Simply escalating oxycodone is risky because it adds sedation and respiratory depression without reliably overcoming the occupancy. The sublingual naloxone in the combination product is not the main explanation; its systemic bioavailability is low. The practical implication is to avoid treating this as ordinary opioid-naive pain. Continue buprenorphine, use multimodal analgesia, and add a titratable full agonist such as IV fentanyl or hydromorphone with close monitoring. Regional analgesia, acetaminophen, and low-dose ketamine can reduce full-agonist requirements. If analgesia remains inadequate, consult addiction medicine or pain specialists about split dosing or increasing buprenorphine; do not abruptly stop it and precipitate withdrawal.
2. Outline a perioperative analgesic plan, including whether to continue, reduce, or stop buprenorphine, and specify monitoring.
Read the worked answer
Continue buprenorphine at 16 mg/day, or split it as 8 mg twice daily, rather than stopping it 72 hours before surgery; abrupt discontinuation risks withdrawal and destabilizes treatment. Use multimodal analgesia: acetaminophen 1 g every 6 hours up to 3 g/day, a fascia iliaca or spinal/regional technique if appropriate, and low-dose ketamine in the operating room. For breakthrough pain, titrate IV fentanyl or hydromorphone in small aliquots and reassess. Expect higher full-agonist requirements because of receptor occupancy. Avoid mixed agonist-antagonists such as butorphanol. Monitor sedation scale, respiratory rate, pulse oximetry, and capnography if he receives repeated parenteral opioids or has sleep-disordered breathing. Coordinate with the addiction treatment prescriber and document the plan. If pain remains severe after surgery, consider increasing buprenorphine to 24 mg/day or transitioning to a full agonist only with a clear monitoring and discharge plan.
3. How would you counsel the patient about the interaction between buprenorphine and full agonists, and what documentation is needed?
Read the worked answer
Explain that buprenorphine is not 'blocking all pain medicine' but is occupying opioid receptors tightly, so ordinary doses may feel weak. Emphasize that adding more opioid at home is dangerous and that the hospital team will titrate short-acting medicines while watching breathing. Clarify that he should not stop buprenorphine on his own and should tell every clinician about it. Document the maintenance dose, the reason for continuing it, the multimodal plan, the full agonist used and response, sedation and respiratory monitoring, and the addiction prescriber contact. Also document that he was warned about sedation and that naloxone is available if he goes home on any opioid. This counseling and documentation support safe prescribing and reduce the chance of stigmatizing him or undertreating his acute pain.